Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Liver Cancer
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Anti-CD3/MUC1-armed cytokine induced killer cells-Benhealth Biopharmaceutical (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Benhealth Biopharmaceutical
- 05 Jan 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified January 2021).
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 27 Jan 2021 Planned End Date changed from 31 Dec 2020 to 28 Jan 2021.